AGEN vs AZN
AGEN: A clinical-stage immuno-oncology company advancing checkpoint immunotherapy and combination therapies, primarily botensilimab, while generating near-term revenue through royalty sales and partnerships. AZN: Leading global biopharmaceutical company developing targeted oncology, cardiovascular, and rare disease treatments backed by a strong R&D pipeline.
Side-by-side fundamentals
| Metric | AGEN | AZN | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.53 | $169.73 | |
| Market cap as of 2026-07-23 | $232M | $193.7B | |
| P/E as of 2026-07-23 | 3.60 | 24.93 | AGEN lower |
| PEG as of 2026-07-23 | n/a | 2.64 | |
| Net margin as of 2026-07-23 | +52.2% | +17.2% | AGEN higher |
| Gross margin as of 2026-07-23 | +99.3% | +81.4% | AGEN higher |
| Operating margin as of 2026-07-23 | +87.9% | +23.7% | AGEN higher |
| ROE as of 2026-07-23 | +76.6% | +22.3% | AGEN higher |
| ROA as of 2026-07-23 | +31.1% | +9.1% | AGEN higher |
| Debt / equity as of 2026-07-23 | 4.01 | 0.72 | AZN lower |
| Revenue growth (YoY) as of 2026-07-23 | +24.5% | +9.9% | AGEN higher |
| Revenue CAGR (3y) SEC XBRL | +5.2% | n/a | |
| Dividend yield as of 2026-07-23 | n/a | +1.9% | |
| Beta as of 2026-07-23 | 1.48 | 1.38 | |
| 1-year return as of 2026-07-22 close | -8.4% | +17.0% | AZN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.